Holen Sie sich die Stockscreener-App
13.31
3.34%
-0.46
Vorhandelsmarkt:
13.38
0.07
+0.53%
Schlusskurs vom Vortag:
$13.77
Offen:
$13.42
24-Stunden-Volumen:
2.78M
Relative Volume:
1.17
Marktkapitalisierung:
$4.18B
Einnahmen:
$3.02B
Nettoeinkommen (Verlust:
$127.93M
KGV:
60.14
EPS:
0.2213
Netto-Cashflow:
$225.64M
1W Leistung:
-9.21%
1M Leistung:
-6.60%
6M Leistung:
+39.52%
1J Leistung:
+51.94%
1-Tages-Spanne:
$13.08
$13.47
1-Wochen-Bereich:
$13.08
$14.84
52-Wochen-Spanne:
$6.685
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.31 | 4.33B | 3.02B | 127.93M | 225.64M | 0.2213 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.26B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.93 | 54.44B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.61 | 48.41B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.28 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
498.65 | 22.12B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat
Truist raises Amneal Pharmaceuticals stock price target on margin focus - Investing.com
Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating - marketscreener.com
Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - simplywall.st
Earnings Miss: Can Amneal Pharmaceuticals Inc be the next market leaderQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Envestnet Asset Management Inc. Takes $1.61 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Amneal Pharmaceuticals beats expectations in Q4 2025 - Investing.com Australia
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) grows biosimilars, Parkinson’s and injectables - Stock Titan
Why Amneal (AMRX) Stock Is Trading Lower Today - Finviz
Amneal Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Amneal Q4 2025 slides: specialty surge drives 11% revenue growth - Investing.com
Amneal Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-02-27 - Seeking Alpha
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million - Benzinga
Amneal Posts Strong Q4 Results and Raises 2026 Outlook - TipRanks
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations - Finviz
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals : Fourth Quarter 2025 Earnings Presentation - marketscreener.com
Amneal Pharmaceuticals beats Q4 estimates, guides below views - Investing.com
AMNEAL PHARMACEUTICALS ($AMRX) Releases Q4 2025 Earnings - Quiver Quantitative
Amneal (NASDAQ: AMRX) returns to profit and guides 2026 growth - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q4 Revenue $814.3M, vs. FactSet Est of $807.4M - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.18 - marketscreener.com
Amneal Pharmaceuticals Reports Strong Full Year 2025 Financial Results and Confident 2026 Guidance - Quiver Quantitative
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
Drugmaker Amneal swings from loss to $72M profit as sales hit $3B - Stock Titan
Amneal Pharmaceuticals earnings on deck amid growth transition - Investing.com
Amneal Pharmaceuticals earnings on deck amid growth transition By Investing.com - Investing.com India
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Trading Momentum And Modest Undervaluation Estimate - simplywall.st
Earnings Outlook For Amneal Pharmaceuticals - Benzinga
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow - Finviz
AMRX Technical Analysis & Stock Price Forecast - Intellectia AI
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo Finance
Jobs Data: Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Dividend Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
Gains Recap: Will Global Ship Lease Inc stock hit new highs in YEARJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Hillsdale Investment Management Inc. Acquires 715,229 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Is Amneal Pharmaceuticals Inc in a long term uptrendQuarterly Profit Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is Amneal Pharmaceuticals Inc. stock undervalued right nowM&A Rumor & Weekly High Momentum Picks - mfd.ru
Will Amneal Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Snapshot & Weekly Top Gainers Trade List - mfd.ru
What are the future prospects of Amneal Pharmaceuticals Inc.Gap Up & Weekly Top Performers Watchlists - mfd.ru
Aug PreEarnings: How sensitive is Amneal Pharmaceuticals Inc to inflationJuly 2025 Trends & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? - Finviz
Does S&P SmallCap 600 Entry And Parkinson’s Deal Reshape The Bull Case For Amneal Pharmaceuticals (AMRX)? - Sahm
Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD By Investing.com - Investing.com Canada
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):